My watch list
my.chemeurope.com  
Login  

Etravirine



Etravirine (TMC-125) is an drug currently under investigation for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTIs). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to entravirine. Etravirine is being developed by Tibotec, a subsidiary of Johnson & Johnson. The Food and Drug Administration is scheduled to review the safety and efficacy data for etravirine in early 2008.[1]

Additional recommended knowledge


  1. ^ Stellbrink HJ. Antiviral drugs in the treatment of AIDS: what is in the pipeline? Eur J Med Res. 2007 Oct 15;12(9):483-95. PMID: 17933730
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Etravirine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE